Overview

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The main goal is to provide additional information to the risk-benefit assessment of the drug.
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen Research & Development, LLC
Treatments:
Rivaroxaban